Resonance Health (RHT.AX) Akcija Цена

Resonance Health Цена

ASX·ZATVORENO
0,08
​
Tržište je zatvoreno

Prihod je rastao 11,9 % godišnje u poslednjih 19 godina na 15,75 М AUD. Zarada po akciji rasla je 3,8 % godišnje u poslednjih 17 godina. neto marža kompanije Resonance Health sada iznosi 9,6 %, porasla sa -29,8 % pre nekoliko godina.

Cena akcije Resonance Health

Pristupite ovim podacima preko Eulerpool API-ja

Resonance Health poslovni model i analiza akcije

Resonance Health Ltd je australijska kompanija koja posluje u industriji medicinske tehnologije. Poslovni model kompanije ogleda se u pružanju revolucionarnih rešenja za dijagnostikovanje i lečenje bolesti jetre i poremećaja vezanih za gvožđe. Kao pionir u razvoju metoda i tehnologija za kvantifikaciju koncentracije gvožđa i stanja jetre, Resonance Health stalno postavlja nove standarde u industriji. Kompaniju je 2000. godine osnovao tim stručnjaka iz oblasti biomedicine sa Univerziteta Zapavne Australije. Tokom godina, kompanija je stekla značajno iskustvo i kontinuirano se razvijala kako bi pratila napredak medicinske tehnologije. Cilj je pružiti pacijentima bolju terapiju i poboljšan kvalitet života. Jedan od odelika kompanije bavi se razvojem i proizvodnjom dijagnostičkih alata za kvantifikaciju bolesti jetre i nivoa gvožđa, kao što su hepatitis, masna jetra ili hemohromatoza. Metoda kvantifikacije koju koristi Resonance Health naziva se FerriScan. Ova metoda je neinvazivna i bezbolna, koristeći magnetnu rezonancu (MRI) za merenje koncentracije gvožđa u tkivu. Ovo je posebno važno jer promena sadržaja gvožđa može ukazivati na progresiju bolesti jetre. Pored dijagnostičkog alata FerriScan, Resonance Health takođe nudi softverski paket za analizu rezultata FerriScan-a, koji koriste lekari i kliničari za procenu progresije bolesti. Štaviše, kompanija razvija i rešenja u oblasti hemohromatoze, genetskog poremećaja koji može dovesti do povišenog nivoa gvožđa u telu. Drugi odeljak Resonance Health-a pruža usluge istraživanja i razvoja kako bi se dalje unapredili FerriScan i druge tehnologije. Kompanija sarađuje sa drugim kompanijama, naučnim institucijama i univerzitetima kako bi unapredila trenutni razvoj dijagnostike bolesti jetre i gvožđa. Resonance Health ima širok spektar proizvoda koji doprinose boljoj dijagnostici i lečenju bolesti jetre i poremećaja vezanih za gvožđe. To uključuju FerriScan, softverski paket FerriSmart za precizno praćenje zdravlja jetre i nivoa gvožđa, kao i Hepatica, softver koji podržava bolnice i klinike u dijagnostici bolesti jetre. Kompanija je inovativni lider u industriji, koji doprinosi poboljšanju kvaliteta života pacijenata. Proizvodi i usluge Resonance Health-a pomogli su lekarima i kliničarima da efikasno dijagnostikuju i leče bolesti jetre i poremećaje vezane za gvožđe. Dodatno, kompanija je izgradila čvrstu naučnu osnovu i usko sarađuje sa vodećim institucijama kako bi kontinuirano razvijala inovativna rešenja. Resonance Health je kompanija bogate istorije koja se nastavlja razvijati kako bi zadovoljila zahteve industrije medicinske tehnologije. Kompanija teži da kontinuirano unapređuje dijagnostiku i lečenje bolesti jetre i poremećaja vezanih za gvožđe, nudeći bolje rešenja.

Često postavljana pitanja o akciji Resonance Health

The business model of Resonance Health Ltd focuses on providing innovative medical imaging software and services. The company aims to improve patient care and outcomes through its advanced technology solutions. Resonance Health specializes in the development and commercialization of non-invasive diagnostic tools, particularly in the field of liver and cardiac diseases. By leveraging its expertise in quantitative analysis and iron overload assessment, Resonance Health offers reliable and efficient solutions for diagnosing and managing various health conditions. The company operates by licensing its software to medical institutions and partnering with healthcare providers, ensuring widespread accessibility and utilization of its cutting-edge technologies.

Resonance Health Ltd is primarily active in the healthcare and medical technology industries.

The main competitors of Resonance Health Ltd in the market include other companies operating in the medical diagnostics and healthcare sector. Some prominent competitors are InHealth Group, Q BioMed, and Novartis AG. Resonance Health Ltd faces competition from these companies in developing innovative diagnostic solutions and providing high-quality healthcare services.

Resonance Health Ltd. is a leading provider of automated, non-invasive medical imaging software and analysis services. Founded in 1987, the company has a rich history of innovation and expertise in the field of liver and cardiac MRI imaging. Resonance Health's technology allows for accurate and reliable diagnosis of liver iron concentration and cardiac ejection fraction, essential measurements for monitoring patients with iron overload and heart conditions. With a strong commitment to research and development, Resonance Health continues to develop cutting-edge solutions that improve patient outcomes and streamline healthcare processes. As a trusted name in the industry, Resonance Health Ltd. has gained recognition globally for its advanced medical imaging products and services.

Resonance Health Ltd, a leading company in the healthcare sector, has accomplished several significant milestones. One noteworthy achievement is the development of FerriScan®, an advanced diagnostic tool for measuring liver iron concentration. Through extensive research and innovative technology, Resonance Health Ltd has revolutionized the diagnosis and monitoring of iron overload disorders such as hereditary hemochromatosis and thalassemia. The company has also expanded its global presence by establishing partnerships with renowned medical institutions and securing regulatory approvals for its groundbreaking products. With a relentless commitment to advancing patient care, Resonance Health Ltd continues to make remarkable strides in the field of medical diagnostics.

Resonance Health Ltd is primarily present in multiple countries and regions across the world. With its global reach, the company has established a strong presence in key markets. Its operations span across Australia, the United States, Europe, and Asia-Pacific regions. Resonance Health Ltd's commitment to expanding its footprint internationally has enabled it to serve a diverse range of customers and collaborate with partners on a global scale. This global presence reinforces Resonance Health Ltd's position as a leading player in the industry while allowing it to leverage various market opportunities and better serve its stakeholders.

Resonance Health Ltd represents values of innovation, excellence, and integrity in its corporate philosophy. As a leading stock health company, Resonance Health Ltd focuses on utilizing advanced technology and research to improve the diagnosis and treatment of liver diseases and iron disorders. With a dedicated team of experts, the company prioritizes accuracy and efficiency in its solutions, delivering reliable results to healthcare professionals worldwide. Resonance Health Ltd strives to enhance patient care by providing precise diagnostic tools, earning recognition for its commitment to quality and advancing medical knowledge.

Po trenutnom kursu akcija Resonance Health kotira 0,05 EUR (0,08 AUD).

Akcija Resonance Health (RHT.AX) kotira na 1 berze, uključujući: ASX (RHT.AX).

Resonance Health Ltd is a medical technology and software company specializing in the development and marketing of medical imaging devices, software, and services. The company is based in Perth, Australia, and operates worldwide.

prihod od Resonance Health je 15,75 М AUD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

dobit od Resonance Health je 1,51 М AUD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Resonance Health je trenutno 25,82. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Resonance Health.

Odnos cene i prihoda (KUV) za Resonance Health je trenutno 2,48. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Resonance Health.

Eulpool score kvaliteta za Resonance Health je 5/10.

ISIN za Resonance Health je AU000000RHT2. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Resonance Health je A0BK8V. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Resonance Health je RHT.AX. Simbol tikera se koristi za trgovinu akcijama Resonance Health na berzanskom tržištu.

Фер вредностTerminal
0,07 AUD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Медицинска опрема и понуде
Број акција
Запослени
Приход по запосленом
875.106,06 AUD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт resonancehealth.com
Земља
Аустралија
Валута
AUD
Јавна понуда
23. окт 1987.
ISIN
AU000000RHT2
CUSIP
Q8109K100
SEDOL
6006369
Тржишна капитализација
37,34 М AUDMicro Cap
Опсег од 52 недеље
AAQS
5 / 10
PEG
—
P/E однос
P/Ee 2027
—
P/S
P/Se
—
EV/EBIT
23,70
P/B однос
3,36
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
10,14 %
Zadnje ažurirano 13. окт 2026. 21:42

Resonance Health Тикер

ASX · RHT.AX

Resonance Health FIGI

RHT:AU · BBG000BWR569RHT:AT · BBG000BWR5D1RHT:AH · BBG002F3GJ30RSHTF:PQ · BBG002K3R5B3RSHTF:UV · BBG002K3R5D1RHTEUR:EO · BBG005XKW4G6RHTEUR:XH · BBG005XKW4K1RHTEUR:XF · BBG005XKW4M9RHTEUR:XE · BBG005XKW4P6RHTEUR:XJ · BBG005XKW4Q5RHTEUR:XL · BBG005XKW4R4RHTEUR:XG · BBG005XKW4S3